Wholesale OEM Cell & Gene Therapy Product, Service

Zhejiang Bioland Biotechnology Co., Ltd. is at the forefront of innovation in the field of cell and gene therapy products and services. With a commitment to advancing biotechnological solutions, we specialize in providing high-quality wholesale OEM products tailored to meet the unique needs of our global partners. Our extensive portfolio includes cutting-edge therapeutic vectors, cell culture media, and advanced gene editing tools, all developed in compliance with international standards. Leveraging state-of-the-art facilities and a team of experienced professionals, we ensure that our offerings not only meet but exceed the expectations of our clients, As a reliable partner for businesses around the world, we pride ourselves on our ability to deliver customized solutions that empower researchers and developers in their quest for groundbreaking treatments. Our collaborative approach means that we work closely with you to understand your requirements and develop products that align with your goals. Whether you are a biotech startup or an established pharmaceutical company, Zhejiang Bioland Biotechnology Co., Ltd. is dedicated to supporting your journey in the rapidly evolving landscape of cell and gene therapy, helping you turn innovative ideas into reality and make a significant impact on human health

Hot Selling Product

Bioland™ Cell Culture Microplates

Bioland™ 96 Well Black/Clear Bottom Plate, TC Surface

Bioland™ Vortex Mixer MVM-3000

Bioland™ QPCR 96-well plate

Bioland™ Teflon® Rigid Tubing

Today's Choice of Cell & Gene Therapy Manufacturers You Can Rely On Your End-to-End Solution

In the evolving landscape of biotechnology, cell and gene therapies have emerged as revolutionary approaches to treating various diseases. As a global buyer, choosing the right manufacturing partner is critical for ensuring the success of your biopharmaceutical projects. Today's market presents a multitude of manufacturers, but few can offer the comprehensive support and reliability necessary for a seamless end-to-end solution. By collaborating with a manufacturer that provides a full suite of bioconsumables and tailored research support, you can streamline your development process from early research to final product launch. This approach not only accelerates timelines but also enhances the potential for innovative therapies to reach the market effectively. With a focus on quality and compliance, a dedicated manufacturing partner can help you navigate complex regulatory landscapes while ensuring that your products meet the highest standards. Investing in a strategic partnership with a reputable manufacturer means gaining access to a wealth of expertise in biotechnological research and product development. Such collaborations can empower you to transform bold ideas into viable therapies that improve patient outcomes and contribute to global health advancements. As you assess your options, consider the long-term benefits of aligning with a partner that shares your commitment to innovation and excellence in biopharmaceutical development.

Today's Choice of Cell & Gene Therapy Manufacturers You Can Rely On Your End-to-End Solution

Manufacturer Type	Service Offered	Therapeutic Area	Certifications	Manufacturing Capacity
Cell Therapy	Process Development	Oncology	ISO 13485	10,000 L
Gene Therapy	Vector Production	Neurology	FDA GMP	5,000 L
Cell Therapy	Clinical Trial Support	Autoimmune Disorders	EMA Certification	15,000 L
Gene Therapy	Regulatory Affairs	Rare Diseases	ISO 9001	8,000 L

Growth Trends in Cell & Gene Therapy Manufacturing Capacity (2018-2023)

The growth of cell and gene therapy manufacturing capacity has shown a remarkable upward trend from 2018 to 2023. Over the last six years, the capacity of manufacturers has escalated dramatically from 5 million units in 2018 to an impressive 60 million units in 2023. This trend is indicative of the increasing investments and advancements in biotech processes aimed at enhancing the efficiency and effectiveness of these therapies. In 2019, we observed a significant leap as the capacity doubled, setting a strong foundation for continuous growth in the following years. By 2021, the momentum gained speed, reflecting the industry's response to burgeoning demand for innovative treatments. The data suggests that the concerted efforts of manufacturers to fine-tune their production methodologies and scale operations have paid dividends in meeting the complex needs of the market. As we move towards 2024 and beyond, the expectation is that this growth trajectory will continue, supported by scientific breakthroughs and regulatory advancements that further enable cell and gene therapies to revolutionize healthcare.